抗體藥物複合體 (ADC)：肺癌治療新希望 Antibody-Drug Conjugates (ADC): A New Hope in Lung Cancer Treatment @健康11·直播

腫瘤科吳教恩醫師
腫瘤科吳教恩醫師
2 觀看·2026年2月8日

抗體藥物複合體（ADC）是結合抗體與化療藥物的新型抗癌武器，能精準攻擊癌細胞，同時減少對健康細胞的損害。在肺癌治療中，ADC正展現其突破性的潛力，尤其對於標靶與免疫治療效果有限的病患。本影片將介紹ADC的原理、在肺癌中的應用、目前研究進展與未來發展方向，讓大家了解這個新興療法如何改變癌症治療的格局。

Antibody-drug conjugates (ADC) combine the precision of antibodies with the potency of chemotherapy to target cancer cells while sparing healthy tissues. In lung cancer treatment, ADC is emerging as a groundbreaking therapy, especially for patients with limited response to targeted and immunotherapies. This video explores the mechanism of ADCs, their application in lung cancer, ongoing research, and future potential, offering insights into how this innovative approach is reshaping cancer treatment.